| UNIVERSITY OF ZURICH Patent applications |
| Patent application number | Title | Published |
|---|
| 20120061568 | METHOD AND APPARATUS FOR MOTION RECOGNITION - A motion recognizing apparatus and method are provided. According to an aspect, a motion recognizing apparatus may include: an optical sensor configured to sense at least a portion of a subject where a motion occurs and to output one or more events in response thereto; a motion tracing unit configured to trace a motion locus of the portion where the motion occurs based on the one or more outputted events; and a motion pattern determining unit configured to determine a motion pattern of the portion where the motion occurs based on the traced motion locus. | 03-15-2012 |
| 20120004395 | Use Of Serine Protease Inhibitors In The Treatment Of Neutropenia - The invention relates to therapeutic compounds which are inhibitors of serine proteases, to pharmaceutical compositions thereof and to their use in the treatment of the human or animal body. More specifically, the present invention relates to a method for the treatment of neutropenia comprising the administration to a subject in need thereof of a therapeutically effective amount of a serine protease inhibitor. The invention also comprises prevention of apoptosis of myeloid cells (1) during and after transfection of bone marrow cells performed for gene therapy, (2) during blood stem cell mobilization performed for reconstitution of hematopoiesis and (3) during infusion of cells of the myeloid lineage for reconstitution of hematopoiesis for gene therapy or for treatment of neutropenia by infusion of neutrophils. | 01-05-2012 |
| 20110300077 | Human Anti-Alpha-Synuclein Antibodies - Provided are human alpha-synuclein-specific autoantibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for α-synuclein are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for α-synuclein targeted immunotherapy and diagnosis, respectively. | 12-08-2011 |
| 20110223303 | RESISTANCE GENES - The present invention relates to polynucleotides encoding adult plant pathogen resistance proteins. Also provided are transgenic plants expressing these polynucleotides to enhance the resistance of the plants to pathogens. | 09-15-2011 |
| 20110182809 | Method of Promoting Neurogenesis - The present description relates generally to methods of using Abeta binding molecules including, for example, antibodies and antibody fragments that recognize Abeta. The description provides methods of promoting neurogenesis, angiogenesis, synaptic activity and/or dendritic arborization using Abeta binding molecules. The description also provides methods of treating various diseases, disorder, injuries and conditions associated with amyloid plaques or the accumulation of Abeta. | 07-28-2011 |
| 20110177120 | MYCOBACTERIUM TUBERCULOSIS VACCINE - The present invention relates to the use of live mycobacterium of the | 07-21-2011 |
| 20110165808 | SUPERHYDROPHOBIC COATING - A composition for coating comprising at least one compound of formula I and optionally at least one compound of formula II | 07-07-2011 |
| 20110123447 | METHOD OF PROVIDING HUMAN TUMOR-SPECIFIC ANTIBODIES - Provided are novel tumor-specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize tumor-associated antigens and that are obtained from a tumor patient who shows at least partial clinical response or is symptom-free. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of tumors are described. | 05-26-2011 |
| 20110027284 | NOGO-A BINDING MOLECULES AND PHARMACEUTICAL USE THEREOF - The present invention provides a binding molecule which is capable of binding to the human NogoA polypeptide or human NiG with a dissociation constant<1000 nM, a polynucleotide encoding such binding molecule; an expression vector comprising said polynucleotide; an expression system comprising a polynucleotide capable of producing a binding molecule; an isolated host cell which comprises an expression system as defined above; the use of such binding molecule as a pharmaceutical, especially in the treatment of a disease of the peripheral (PNS) and/or central (CNS) nervous system; a pharmaceutical composition comprising said binding molecule; and a method of treatment of a disease of the peripheral (PNS) and/or central (CNS) nervous system. | 02-03-2011 |
| 20100310543 | METHOD OF PREVENTING AND TREATING ACUTE BRAIN PATHOLOGIES - Described are novel means in the treatment of cerebral neurological conditions such as ischemic insult of the brain. Furthermore, a kit for a non-radioactive protein serine/threonine phosphatase activity assay is provided, which is capable of detecting and distinguishing the activity of PP1, PP2A, and calcineurin (PP2B). | 12-09-2010 |
| 20100292563 | Optical MRI device - A dual modality imaging apparatus, comprising a magnetic resonance imaging (=MRI) system and a fluorescence molecular tomography (=FMT) system, for investigating a sample ( | 11-18-2010 |
| 20100202968 | Method of Providing Disease-Specific Binding Molecules and Targets - Provided are novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize neoepitopes of disease-associated proteins which derive from native endogenous proteins but are prevalent in the body of a patient in a variant form and/or out of their normal physiological context. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of neurological disorders such as Alzheimer's disease are described. | 08-12-2010 |
| 20090305992 | USE OF AN INTERLEUKIN 1 RECEPTOR ANTAGONIST AND/OR PYRROLIDINEDITHIOCARBAMATE FOR THE TREATMENT OR PROPHYLAXIS OF TYPE 2 DIABETES - Substances that inhibit the action of the members of the IL-1β/NF-κB pathway can be used for protecting and preserving β-cell mass and function in prediabetic and diabetic type 2 patients. Specifically, the present invention relates to the use of an Interleukin 1 receptor antagonist (IL-1Ra) and/or pyrrolidinedithiocarbamate (PDTC) for the treatment or prophylaxis of type 2 diabetes, as well as a method for the treatment of type 2 diabetes. | 12-10-2009 |
| 20090214543 | METHODS FOR TREATING CANCER USING AN IMMUNO-TOXIN COMPRISING AN EXOTOXIN A MOIETY HAVING A FURIN CLEAVAGE SITE REPLACED WITH A CANCER ASSOCIATED PROTEASE SITE CLEAVED BY MMP-2 OR MMP-9 - The present invention provides a modified toxin having an ETA moiety that has the furin site replaced with a cancer-associated protease site. The present invention also provides modified immunotoxins having a ligand that binds to a cancer cell attached to an ETA moiety that has the furin site replaced with a cancer-associated protease site. Also provided are a method of inhibiting or destroying mammalian cancer cells using the immunotoxins of the invention and pharmaceutical compositions for treating human cancer. | 08-27-2009 |
| 20090048457 | PROCESS FOR PREPARATION OF RACEMIC NEBIVOLOL - A process of making racemic [2S*[R*[R*[R*]]]] and [2R*[S*[S*[S*]]]]-(±)α,α′-[iminobis(methylene)]bis[6-fluoro-3,4-dihydro-2H-1-benzopyran-2-methanol] of the compound of the formula (I) and its pure [2S*[R*[R*[R*]]]]- and [2R*[S*[S*[S*]]]]-enantiomer compounds and pharmaceutically acceptable salts thereof. | 02-19-2009 |
| 20080317710 | Methods For Treating Autoimmune or Demyelinating Diseases - The present invention relates to novel therapeutic or prophylactic treatment in human subjects. The present invention results in part from the discovery that antagonists of IL-18Rα are effective in vivo for treating diseases. Accordingly, the invention provides a method of treating, preventing or ameliorating the symptoms of an autoimmune or demyelinating disease (such as multiple sclerosis) in a subject, preferably a human subject, said method comprising administering to the subject a therapeutically effective amount of an antagonist of IL-18Rα. The invention also pertains to the use of an antagonist of IL-18Rα in the manufacture of a medicament for the treatment of an autoimmune or demyelinating diseases (such as multiple sclerosis). | 12-25-2008 |
